WCLC 2022 – Filiz Oezkan
Filiz Oezkan depicts the most important factors influencing the choice of treatment in patients with PD-L1-positive NSCLC, explains how the 50 % PD-L1 threshold affects the treatment selection and explains which treatment options appear favorable in the setting of PD-L1 levels below 1 % while also taking into account possible challenges associated with biomarker testing for PD-L1 in NSCLC.
Here is the full WCLC 2022 report.
More posts
Immune-based strategies are raising hope in small-cell tumors
Immune-based strategies are raising hope in small-cell tumors DeLLphi-300: tarl
Stage I-III disease: surgical and systemic options
Stage I-III disease: surgical and systemic options SLR as new standard of care
Promising findings across oncogenic targets
Promising findings across oncogenic targets Amivantamab plus lazertinib in EGFR
Preface – WCLC 2022
Preface – WCLC 2022 © Private – Michael Thomas, MD, PhD, Head of the Depar
